Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06264908

An Integrated Self Management Programme to Improve Outcomes in Patients With Hand Osteoarthritis

The goal of this trial is to evaluate the efficacy of an integrated self-management programme in improving clinical outcomes in patients with hand osteoarthritis (OA).

This is an open-labelled, randomized controlled trial with an objective to determine the efficacy of an integrated self-management programme versus routine clinical care for participants with symptomatic hand OA.

Participants will be randomized into early intervention group and routine clinical care groups in a 1:1 ratio. Patients who randomized into early intervention group will receive 8 week integrated self-management programme delivered by occupational therapists and rheumatology nurse on hand OA management. Patients who randomized into routine clinical care group will receive usual clinical care for OA for 26 weeks and then receive an identical 8 weeks integrated self-management programme. The primary outcome is the improvement in pain at 26 weeks between the two groups.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Background: Osteoarthritis (OA) of the hand is a common and potentially disabling condition with increasing prevalence in Hong Kong due to an aging population. The direct and indirect economic burden due to OA are substantial and this calls for an unmet need for more effective management for hand OA. Hand OsteoArthritis Self-management and Integrated Scheme (OASIS-H) is a self-management programme integrated with occupational therapy and rheumatology nurse education with an aim to improve outcomes in patients with hand osteoarthritis.

Objective: This is an open-labelled, randomized controlled trial to determine the efficacy of an integrated self-management programme versus routine clinical care for participants with symptomatic hand OA.

Hypothesis: The integrated programme will be more efficacious than routine clinical care in reducing pain and improving function in symptomatic OA hand in 6 months.

Methods: Consecutive patients who fulfilled the American College of Rheumatology Classification Criteria for hand OA with a pain score of ≥40 out of 100mm on visual analogue scale (VAS) will be included. Patient with secondary OA hand, unable to sign consent and with the use of systemic corticosteroid within 6 months will be included. Participants will be randomized in a 1:1 ratio into early intervention and routine clinical care groups. In the early intervention group, patients will participate in an eight-week integrated hand OA management programme within 1 month from randomization. The programme will consist of three self-management education sessions conducted by the occupational therapists and rheumatology nurses on pain management strategy, joint protection, group sharing and exercise, one telemedicine session, aids prescription and splintage fabrication. For patients randomized into the routine clinical care group, they will continue to receive routine medical care from the rheumatology clinic. At 6 months after randomization, patients in the routine clinical care group will crossover and receive an identical 8-week integrated hand OA management programme as the early intervention group. The primary endpoint is the change in finger pain in pain VAS at 6 months from baseline. Secondary endpoints include change in function measured by the functional index for functional index for hand OA, Short form health survey and health assessment questionnaire disability index, change in hand grip strength and dexterity at 6 months and 12 months. The primary endpoint will be analyzed by linear mixed models and the differences in pain over time between the two groups will be compared using linear regression model.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fulfil the American College of Rheumatology hand osteoarthritis classification criteria
  • Symptomatic hand osteoarthritis with a pain visual analogue score (VAS) equal to or more than 40/100mm within 2 weeks of study entry

Exclusion criteria

  • Secondary hand osteoarthritis from inflammatory arthritis including rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, gouty arthropathy or connective tissue diseases;
  • Receive systemic corticosteroids (other than topical or inhalational) within 6 months of study entry
  • Inability to sign informed consent

Treatment and study plan

Integrated self-management programme

Behavioral

8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.

  • Disease pathology and Pain management
  • Joint protection and stretching exercise
  • Psychosocial education
  • Aids prescription Each session will consist of education session, exercise session and group sharing sessions.

Primary outcomes

  1. Change in Pain visual analogue scale (VAS)

    Time frame: 26 weeks

    Pain VAS reflects the severity of pain in a score of 0-100. A lower score indicates less pain.

Secondary outcomes

  1. Change in pain Visual Analogue Scale (VAS)

    Time frame: 12weeks, 52 weeks

    Pain VAS reflects the severity of pain in a score of 0-100. A lower score indicates less pain.

  2. Change in Functional index hand osteoarthritis (FIHOA)

    Time frame: 12 weeks, 26 weeks, 52 weeks

    FIHOA reflects hand function with a score of 0 to 30. A lower score indicates better hand function

  3. Change in Quick Disabilities of the Arm, Shoulder, and Hand (DASH) score

    Time frame: 12 weeks, 26 weeks, 52 weeks

    QuickDASH is a self-reported 11-itemed questionnaire in which the response options are presented as 5-point Likert scales. At least 10 of the 11 items must be completed for a score to be calculated and the scores range from 0 (no disability) to 100 (most severe disability)

  4. Change in Australian/Canadian Hand Osteoarthritis Index (AUSCAN) 3.1

    Time frame: 12 weeks, 26 weeks, 52 weeks

    AUSCAN 3.1 hand osteoarthritis index is a self-administered questionnaire that assesses the three dimensions of pain, disability and joint stiffness in hand osteoarthritis using a battery of 15 questions. The score is expressed in 3 subscores: AUSCAN pain score (0 (least painful)-100 (most painful), the AUSCAN stiffness score (0: least stiffness-100: most stiffness), the AUSCAN function score (0: least function impairment-100: most severe function impairment)

  5. Change in Short-form 36 items health survey

    Time frame: 26 weeks, 52 weeks

    Short-form 36 items health survey measures 8 domains of health related quality of life. The score is expressed in 0 - 100. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

  6. Change in hand grip strength

    Time frame: 26 weeks, 52 weeks

    Hand grip strength measured by dynamometer

  7. Change in hand dexterity measurement

    Time frame: 26 weeks, 52 weeks

    Hand dexterity measurement

  8. Radiographic changes

    Time frame: 52 weeks

    Measured by hand plain radiographs

Other outcomes

  1. Adverse events

    Time frame: up to 52 weeks

    Adverse events

  2. Use of rescue pain medication

    Time frame: up to 52 weeks

    Use of rescue pain medication e.g. NSAIDS / steroids

Study contacts

Contact information is provided by the study sponsor or research team.

Iris Tang, MBBS

CONTACT

[email protected]

+852-22555999

Sponsors and collaborators

Lead sponsor

Dr Iris Tang Yan Ki

Other

Collaborators

  • Hospital Authority, Hong Kong

Registry information

Official study title

Hand OsteoArthritis Self-management and Integrated Scheme (OASIS-H) to Improve Outcomes in Patients With Hand Osteoarthritis

Acronym: OASIS-H

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Feb 20, 2024
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.